首页> 美国卫生研究院文献>International Journal of Nanomedicine >Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: initial considerations
【2h】

Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: initial considerations

机译:通过单光子发射计算机断层摄影术在诱导动物中用于三阴性乳腺癌成像的抗MUC1纳米适体:初步考虑

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The early and specific detection of tumors remains a barrier in oncology, especially in cases such as the triple-negative breast cancer (TNBC). To address this gap, aptamers have found an important application in the recognition of tumor biomarkers such as mucin 1 (MUC1). However, there are still some difficulties in the use of aptamer, as their rapid biological clearance makes their use as drugs limited. In this study, the anti-MUC1 aptamer was used as a drug delivery system (DDS) for a radioactive polymeric nanoparticle (NP) in the imaging of TNBCs. Thus, poly(lactic-co-glycolic acid) NPs loaded with the anti-MUC1 aptamer and labeled with technetium-99m were used for a biodistribution study and imaging of TNBC. The results confirmed that the NP was successfully obtained, with a mean size of 262 nm, according to the dynamic light scattering data. The biodistribution assay in induced animal models with TNBC showed that although there was a high capture by intestine (>30%), the DDS developed had a high tumor uptake (5%) and with great in vivo imaging properties, corroborating the possibility of use of this DDS as an imaging drug for TNBC.
机译:肿瘤的早期和特异性检测仍然是肿瘤学的障碍,尤其是在三阴性乳腺癌(TNBC)等病例中。为了解决这个空白,适体已经在识别诸如粘蛋白1(MUC1)的肿瘤生物标志物中发现了重要的应用。然而,由于适体的快速生物清除使得其作为药物的使用受到限制,因此在使用适体方面仍然存在一些困难。在这项研究中,抗MUC1适体在TNBC成像中用作放射性聚合物纳米颗粒(NP)的药物输送系统(DDS)。因此,负载有抗MUC1适体并标记有99m的聚乳酸-乙醇酸纳米粒被用于TNBC的生物分布研究和成像。结果证实,根据动态光散射数据,成功获得了NP,平均粒径为262 nm。 TNBC诱导的动物模型中的生物分布分析表明,尽管肠道捕获率高(> 30%),但开发的DDS却具有很高的肿瘤吸收率(5%),并且具有出色的体内成像特性,从而证实了其使用可能性DDS作为TNBC的成像药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号